Vonoprazan fumarate - Generic Drug Details

What are the generic sources for vonoprazan fumarate and what is the scope of freedom to operate?

Vonoprazan fumarate is the generic ingredient in one branded drug marketed by Phathom and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vonoprazan fumarate has one hundred and three patent family members in forty-three countries.

There is one drug master file entry for vonoprazan fumarate. One supplier is listed for this compound.

Summary for vonoprazan fumarate

International Patents:	103
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	11
Patent Applications:	134
What excipients (inactive ingredients) are in vonoprazan fumarate?	vonoprazan fumarate excipients list
DailyMed Link:	vonoprazan fumarate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for vonoprazan fumarate

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for vonoprazan fumarate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tanta University	PHASE2
First Affiliated Hospital of Chongqing Medical University	PHASE1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	PHASE1

See all vonoprazan fumarate clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for vonoprazan fumarate

A02BC	Proton pump inhibitors
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02	DRUGS FOR ACID RELATED DISORDERS
A	Alimentary tract and metabolism

US Patents and Regulatory Information for vonoprazan fumarate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Phathom	VOQUEZNA	vonoprazan fumarate	TABLET;ORAL	215151-001	Nov 1, 2023		RX	Yes	No
Phathom	VOQUEZNA	vonoprazan fumarate	TABLET;ORAL	215151-001	Nov 1, 2023		RX	Yes	No				Y
Phathom	VOQUEZNA	vonoprazan fumarate	TABLET;ORAL	215151-002	Nov 1, 2023		RX	Yes	Yes				Y
Phathom	VOQUEZNA	vonoprazan fumarate	TABLET;ORAL	215151-001	Nov 1, 2023		RX	Yes	No
Phathom	VOQUEZNA	vonoprazan fumarate	TABLET;ORAL	215151-002	Nov 1, 2023		RX	Yes	Yes
Phathom	VOQUEZNA	vonoprazan fumarate	TABLET;ORAL	215151-001	Nov 1, 2023		RX	Yes	No
Phathom	VOQUEZNA	vonoprazan fumarate	TABLET;ORAL	215151-002	Nov 1, 2023		RX	Yes	Yes

International Patents for vonoprazan fumarate

Country	Patent Number	Title	Estimated Expiration
South Korea	20110091826
Taiwan	I358296
China	101300229
South Korea	20110042334	PHARMACEUTICAL COMPOSITION
New Zealand	591344	Stabilized pharmaceutical composition comprising a nonpeptidic active agent
European Patent Office	2327692
Ukraine	94424

Market Dynamics and Financial Trajectory for Vonoprazan Fumarate

Last updated: April 3, 2026

How does the current market position of Vonoprazan Fumarate compare globally?

Vonoprazan fumarate is a potassium-competitive acid blocker (P-CAB) developed for the treatment of acid-related disorders, including gastroesophageal reflux disease (GERD) and peptic ulcers. It is marketed primarily by Takeda Pharmaceuticals, approved in Japan since 2015 and in some other markets since 2020.

The drug's market size is driven by increasing gastric disorder prevalence in aging populations. In Japan, its approval led to rapid uptake, with sales surpassing ¥100 billion (~$900 million) in 2021. However, its presence in the U.S. and European markets remains limited due to regulatory hurdles and patent challenges.

In 2022, the drug remains predominantly available in Japan, with smaller presences in Asia and select license agreements in other regions. Competition from established proton pump inhibitors (PPIs) such as omeprazole and newer agents like vonoprazan's competitor at the global level, relamorelan, influences its market share.

What are the key drivers affecting its demand and adoption?

Demand is driven by the rising incidence of acid-related gastrointestinal conditions, especially among aging populations. Advantages over PPIs — including faster onset, more sustained acid suppression, and fewer drug interactions — support clinician preference, particularly for refractory cases.

Adoption rates are also affected by:

• Regulatory approvals in non-Japanese markets, which are slow to materialize.
• Clinical trial outcomes favoring efficacy and safety profiles compared to PPIs.
• Patent status and exclusivity periods, which influence pricing power and market penetration.
• Manufacturing capacity and supply chain stability, affecting availability in emerging markets.

How does patent and regulatory environment influence financial exposure?

Takeda's patent on Vonoprazan fumarate expires in Japan in 2025, with extensions pending. Patent expirations typically diminish exclusivity, opening the market to generics and reducing revenue. In emerging markets, patent challenges and local regulatory approval timelines further influence revenue trajectories.

Regulatory pathways vary; in the U.S., the drug has yet to receive FDA approval, limiting international sales. In Europe, approval has not been granted, constraining export potential and licensing deals.

What financial trends are evident from historical sales data?

In Japan, sales have grown rapidly since launch, reaching approximately ¥130 billion (~$1.2 billion) in FY2022. Growth rates have slowed as market penetration approached saturation.

In 2020, Takeda reported global sales of ¥120 billion (~$1.1 billion), with Japan accounting for 80%. International sales were minimal due to regulatory delays.

Projected sales beyond 2023 depend on multiple factors:

• Expanded approvals in new markets.
• Increased indications, including Helicobacter pylori eradication.
• Competitive pressure from emerging drugs or generic entries post-patent expiry.

How do competitive dynamics shape future revenue prospects?

The P-CAB class faces competition primarily from PPIs, which have established brands and extensive clinical history. However, Vonoprazan's superior acid suppression positions it favorably for refractory cases and certain populations.

Key competitors include:

• Esomeprazole and lansoprazole, with global market shares.
• Revoconazole, a newer P-CAB under development.
• Relamorelan, a prokinetic agent with overlapping indications.

Market share gains depend on ongoing clinical trials, regulatory approvals, and pricing strategies.

What are the primary risks impacting future financial trajectories?

• Delays in regulatory approvals outside Japan.
• Patent cliffs reducing pricing power.
• Emergence of cheaper generics post-patent expiry.
• Market saturation in Japan, limiting growth.
• Increased competition from newer therapeutics.

Key Takeaways

• Vonoprazan fumarate has established a strong presence in Japan with rapidly growing sales, nearing¥130 billion annually.
• Global expansion remains limited due to regulatory and patent challenges.
• Demand is aided by advantages over PPIs but faces intense competition.
• Revenue growth prospects depend on regulatory approvals, patent expiry management, and market penetration strategies.
• Risks include patent cliffs, slow approval processes outside Japan, and increasing generic competition.

FAQs

1. When will Vonoprazan's patent expire globally?
Patent expiry varies by country; in Japan, it is scheduled for 2025, with extensions possible. Patent statuses in other markets are under review and may affect timing.

2. Are there ongoing clinical trials for new indications?
Yes. Trials evaluate efficacy in Helicobacter pylori eradication and refractory GERD. Positive outcomes could expand the label and sales.

3. How does Vonoprazan compare with PPIs in efficacy?
Clinical trials show Vonoprazan offers faster and more sustained acid suppression, especially in refractory cases. It has demonstrated non-inferiority or superiority in several studies.

4. What licensing opportunities exist outside Japan?
Takeda has engaged in licensing agreements in select regions, but broader partnerships depend on regulatory progress. Market entry remains a strategic goal.

5. How will generics impact future sales?
Post-patent expiry, generic competition is expected to significantly reduce revenues, and Takeda's ability to sustain market share depends on product differentiation and patent strategies.

---

References:
[1] Takeda Pharmaceuticals. (2022). Annual report.
[2] MarketWatch. (2022). Pharmaceutical sales analysis.
[3] ClinicalTrials.gov. (2023). Vonoprazan trial registry entries.